Holen Sie sich die Stockscreener-App
59.27
0.64%
-0.38
Handel nachbörslich:
59.27
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$59.65
Offen:
$58.73
24-Stunden-Volumen:
1.67M
Relative Volume:
0.71
Marktkapitalisierung:
$9.23B
Einnahmen:
$1.17B
Nettoeinkommen (Verlust:
$150.71M
KGV:
63.05
EPS:
0.94
Netto-Cashflow:
$245.03M
1W Leistung:
+0.14%
1M Leistung:
+15.63%
6M Leistung:
+12.82%
1J Leistung:
-19.71%
1-Tages-Spanne:
$58.15
$60.08
1-Wochen-Bereich:
$57.85
$61.05
52-Wochen-Spanne:
$46.01
$80.80
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
(612) 379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Vergleichen Sie TECH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
59.27 | 9.29B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-07-09 | Eingeleitet | TD Cowen | Buy |
| 2025-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Bio-Techne (TECH) Analyst Rating Update: TD Cowen Raises Price T - GuruFocus
Earnings Preview: What to Expect From Bio-Techne's Report - inkl
Will Bio Techne Corporation price bounce be sustainableEntry Point & AI Forecasted Entry/Exit Points - newser.com
Earnings Preview: What To Expect From Bio-Techne's Report - Barchart.com
Smart tools for monitoring Bio Techne Corporation’s price actionMarket Movement Recap & Community Supported Trade Ideas - newser.com
Is Bio Techne Corporation stock a contrarian buy2025 AllTime Highs & Free Daily Entry Point Trade Alerts - newser.com
KLP Kapitalforvaltning AS Decreases Stake in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp (TECH) Investor Outlook: Navigating Growth with a 13.65% Potential Upside - DirectorsTalk Interviews
Statistical indicators supporting Bio Techne Corporation’s strengthJuly 2025 Volume & Real-Time Stock Price Movement Reports - newser.com
Bio-Techne Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Legal Advantage Investments Inc. Acquires 5,000 Shares of Bio-Techne Corp $TECH - MarketBeat
ConMed adds Bio-Techne CEO to board of directors - Central New York Business Journal
Bio-Techne (TECH): Valuation Spotlight Following Expanded Oxford Nanopore Partnership and Growth Strategy Realignment - Yahoo Finance
Visual analytics tools that track Bio Techne Corporation performance2025 Trade Ideas & Scalable Portfolio Growth Ideas - newser.com
Bio Techne Corporation stock daily chart insightsEarnings Growth Report & Smart Investment Allocation Insights - newser.com
Can Bio Techne Corporation recover in the next quarterWeekly Stock Summary & Verified Momentum Stock Alerts - newser.com
Will Bio Techne Corporation stock deliver shareholder valueJuly 2025 Momentum & Technical Pattern Based Signals - newser.com
Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032 - Investing News Network
Bio-Techne (TECH) Expands Partnership with Oxford Nanopore Technologies - GuruFocus
Bio-techne expands genetic testing collaboration with Oxford Nanopore - Investing.com
Bio-techne expands genetic testing collaboration with Oxford Nanopore By Investing.com - Investing.com South Africa
Is Bio Techne Corporation (TE1) stock resilient in recession scenariosTrade Entry Report & Reliable Price Action Trade Plans - newser.com
Should You Continue to Hold Bio-Techne Stock in Your Portfolio? - sharewise.com
Citi Sticks to Their Buy Rating for Bio-Techne (TECH) - The Globe and Mail
Bio-Techne (TECH) Receives a Buy from Evercore ISI - The Globe and Mail
Evercore ISI Group Raises Bio-Techne (TECH) Price Target to $72 | TECH Stock News - GuruFocus
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Citi Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
How Bio Techne Corporation stock performs in rate cut cyclesTrade Risk Assessment & Reliable Breakout Stock Forecasts - newser.com
20,000 Shares in Bio-Techne Corp $TECH Purchased by Hunter Perkins Capital Management LLC - MarketBeat
Will Bio-Techne's (TECH) Latest Spatial Biology Tools Reshape Its Edge in Translational Research? - simplywall.st
Bio-Techne (TECH) Surges Over 21% as Healthcare Stocks Rally - GuruFocus
Bio Techne Corporation stock volume spike explained2025 Trade Ideas & Daily Profit Focused Stock Screening - newser.com
Bio-Techne Corp. Hits Day High with 10.2% Surge in Strong Intraday Performance - Markets Mojo
Bio-Techne (TECH): Assessing the Valuation as Shares Continue Their Recent Upward Momentum - simplywall.st
Why Bio Techne Corporation (TE1) stock trades below fair value2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
Can Bio Techne Corporation (TE1) stock beat analyst consensusWeekly Market Report & Low Risk Entry Point Guides - newser.com
Centene, QuidelOrtho, iRhythm, and Bio-Techne Shares Skyrocket, What You Need To Know - The Globe and Mail
Could Spatial Biology Advances Shape Bio-Techne's (TECH) Long-Term Position in Precision Medicine? - Yahoo Finance
Bio-Techne Corp. stock outperforms competitors on strong trading day - MSN
Park Avenue Securities LLC Acquires Shares of 5,244 Bio-Techne Corp $TECH - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Bruker, Agilent, Revvity, Avantor, and Bio-Techne Shares Are Soaring, What You Need To Know - Yahoo Finance
Bio-Techne (TECH) Shares Skyrocket, What You Need To Know - Yahoo Finance
What analysts say about Bio Techne Corporation TE1 stockIPO Market Watch & Free Discover Dynamic Stocks - earlytimes.in
Bio-Techne (NASDAQ:TECH) Trading Up 4.7%What's Next? - MarketBeat
Is Bio Techne Corporation (TE1) stock positioned for secular growthDollar Strength & Real-Time Buy Signal Alerts - newser.com
Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions - The Globe and Mail
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Techne Corp-Aktie (TECH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nusse Roeland | Director |
Aug 25 '25 |
Sale |
56.36 |
17,040 |
960,388 |
44,559 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Option Exercise |
21.84 |
17,040 |
372,154 |
61,903 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Sale |
56.21 |
17,040 |
957,818 |
44,863 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):